<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154258</url>
  </required_header>
  <id_info>
    <org_study_id>CLEX123J1202</org_study_id>
    <nct_id>NCT00154258</nct_id>
  </id_info>
  <brief_title>A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia</brief_title>
  <official_title>An Open Extension Study to Phase IIb Study of Clozapine in Patients With Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long
      term treatment of clozapine in patients with treatment-resistant schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long
      term treatment of clozapine in patients with treatment-resistant schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events during the long term treatment (until NDA approval)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs at every 4 weeks</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests (hematology: at every 1 - 2 weeks, others: at every 4 weeks)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG at every 12 weeks</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echo cardiogram at every 24 weeks</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the symptoms of psychosis at every 8 weeks up to 52 weeks of treatment, thereafter at every 16 weeks</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor side effects at every 8 weeks up to 52 weeks of treatment, thereafter at every 16 weeks</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Clozaril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Attended the previous Phase IIb (core) study

          -  Improved during the core study

          -  No safety issues during the core study

        Exclusion Criteria:

          -  Discontinued the core study

          -  Pregnant or nursing (lactating) women

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3661</url>
    <description>Clinical Trial Results for CLEX123J1202 at Novartis Clinical Trials</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia, treatment-resistant, clozapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

